We have brought together a committed and experienced leadership team with an established track record in commercialization of specialty dermatology products and late stage clinical development in an entrepreneurial environment.
Our Board is comprised of experienced individuals who help guide Biofrontera Inc. as we grow to become a leading U.S.-based biopharmaceutical company commercializing a portfolio of FDA-approved products for the treatment of dermatological conditions.
Biofrontera Inc. (Biofrontera) is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions. With a focus on the fields of photodynamic therapy (PDT) and topical antibiotics, Biofrontera currently commercializes the FDA-approved flagship drug Ameluz® (aminolevulinic acid hydrochloride gel, 10%) in the United States. When used in combination with PDT and Biofrontera’s BF-RhodoLED® lamp, Ameluz®-PDT is indicated for the treatment of actinic keratoses (AK), one of the most common precancerous skin conditions. Biofrontera also commercializes the drug Xepi® (ozenoxacin cream, 1%), FDA-approved for the treatment of impetigo. In collaboration with dermatologists, Biofrontera is fully committed to advancing treatment options and patient care.
Biofrontera Inc. (Biofrontera) is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions. With a focus on the fields of photodynamic therapy (PDT) and topical antibiotics, Biofrontera currently commercializes the FDA-approved flagship drug Ameluz® (aminolevulinic acid hydrochloride gel, 10%) in the United States. When used in combination with PDT and Biofrontera’s BF-RhodoLED® lamp, Ameluz®-PDT is indicated for the treatment of actinic keratoses (AK), one of the most common precancerous skin conditions. In collaboration with dermatologists, Biofrontera is fully committed to advancing treatment options and patient care.
Board Diversity Matrix for BFRI – Biofrontera Inc.
As of 9/1/2022
|
Total Number of Directors |
5 |
| Part I: Gender Identity | Female | Male | Non-Binary |
Did Not Disclose Gender |
|---|---|---|---|---|
|
Directors |
2 |
3 |
|
|
| Part II: Demographic Background | ||||
|---|---|---|---|---|
|
African American or Black |
|
|
|
|
|
Alaskan Native or American Indian |
|
|
|
|
|
Asian |
|
|
|
|
|
Hispanic or Latinx |
|
|
|
|
|
Native Hawaiian or Pacific Islander |
|
|
|
|
|
White |
1 |
3 |
|
|
|
Two or More Races or Ethnicities |
|
|
|
|
|
LGBTQ+ |
|
|
|
|
|
Did Not Disclose Demographic Background |
|
1 |
|
|
660 Main Street, First Floor, Woburn MA 01801
© Biofrontera 2025, All Rights Reserved
120 Presidential Way, Suite 330
Woburn, MA 01801
1-781-245-1325
info-us@biofrontera.com
Investor Relations
ir@bfinc.com
120 Presidential Way, Suite 330
Woburn, MA 01801
1-781-245-1325
info-us@biofrontera.com
INVESTOR RELATIONS CONTACT
Pamela Keck
+49-214-87632-92
us-ir@biofrontera.com
© Copyright 2025, Biofrontera Corp. All rights reserved.
